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e appreciate the comments from Drs. Roik and Opolski on our
ong-term observations in patients with cardiogenic shock who
ere enrolled in the GUSTO (Global Utilization of Streptokinase
nd Tissue-Type Plasminogen Activator for Occluded Coronary
rteries)-I trial (1). One of the important advantages of long-term
atasets is that long-term data are available—along with the
dvantage comes the disadvantage that they are old data on
atients followed up for a long time. That must be kept in mind
ecause the GUSTO-I trial enrolled patients presenting with their
ndex event between 1990 and 1993 from around the world,
ncluding Warsaw, Poland. Many things have changed since then
n the field of acute myocardial infarction and cardiogenic shock.
ust to name a few, we no longer use streptokinase; in fact, it is no
onger even available in the U.S. for use during acute myocardial
nfarction. We now routinely use stents, sometimes even drug-
luting stents, and IIb/IIa inhibitors are now commonly given.
hus treatment strategies have changed dramatically.
The patients included in our long-term follow-up were all
andomized because they had presented with acute infarction as
art of the 41,021-patient cohort. We note that there are many
ubsets of patients with shock, but at the time of the initial
USTO shock publication, this shock substudy was the largest in
he literature. Undoubtedly some subsets have a worse prognosis
han others, and work continues to optimize identification of
igher-risk patients as well as to optimize their outcomes.
As previously documented in the GUSTO-I experience (2),
9% of these patients developed shock after admission using a
efinition of shock of “a systolic blood pressure90 mm Hg for at
east 1 h, not responsive to fluid administration, thought to be
econdary to cardiac dysfunction, and associated with signs of
ypoperfusion.” The fact that the in-hospital mortality was 56%
dentifies that this indeed was a very-high-risk group of patients.
The most important points of our follow-up study are that:
) we need better strategies for optimizing early outcomes of
ardiogenic shock; and 2) as Drs. Hochman and Apolito
ointed out in their accompanying editorial (3), after the initial
torm, there is surprising calm.
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entricular Arrhythmia: A
istorical Perspective
lbert et al. (1), in their important study on the risk of defibrillator
hocks during driving, suggest that their study is “the first to
xamine the association between driving a car and the onset of
entricular arrhythmias.” There were, in fact, a series of publica-
ions, albeit including only a small number of patients, published
ome 40 years ago and performed in patients with a spectrum of
ardiac diseases driving in British traffic (2–4). These studies
ocumented a remarkably high prevalence of ventricular arrhyth-
ias and ST-segment shifts despite the lack of symptoms and even
ncluded 1 patient who developed sustained ventricular tachycardia
clearly illustrated in the article but misrepresented as sinus
achycardia) associated with the development of pulmonary edema
equiring a hospital stay (4).
The apparent discrepancy between the high prevalence of
riving-induced arrhythmia in the early studies and a low fre-
uency of implantable cardioverter-defibrillator shocks in the
igh-risk population enrolled in the current study is striking. On
he assumption that city driving in the U.S. in the 21st century is
s least as stressful as it was in central London in the 1960s, one
onders whether the antiadrenergic effect of beta-blockade might
ccount for these differences. However, reference to the authors’
able 2 indicates this not to be the case, at least in terms of
alignant ventricular arrhythmias. The early studies had a high
roportion of patients with active angina, whereas nowadays
evascularization is the norm in ischemic heart disease. This
ifference in driving-related arrhythmia points to the powerful role
f ischemia in triggering arrhythmias in susceptible patients,
ighlights how far we have come in the past 40 years, and
nderscores the enduring value of now-historic studies for gaining
nsight into potential mechanisms of disease. To paraphrase a
ell-known saying: “She who knows history may be destined to
mprove it.”
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